- Home
- THRD
as 12-20-2024 4:00pm EST
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 513.2M | IPO Year: | 2022 |
| Target Price: | $20.33 | AVG Volume (30 days): | 259.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.08 - $16.94 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Third Harmonic Bio Inc. (THRD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Conner Edward R. | THRD | Chief Medical Officer | Nov 8 '24 | Sell | $15.00 | 2,117 | $31,755.00 | 0 | |
| BVF PARTNERS L P/IL | THRD | N/A | Oct 29 '24 | Sell | $14.30 | 1,000,000 | $14,300,000.00 | 1,794,218 | |
| Conner Edward R. | THRD | Chief Medical Officer | Oct 28 '24 | Sell | $15.00 | 2,673 | $40,095.00 | 0 |
Latest Third Harmonic Bio Inc. News
THRD Breaking Stock News: Dive into THRD Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
Zacks
a month ago
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade
GlobeNewswire
a month ago
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
GlobeNewswire
a month ago
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 11/01/2024
Simply Wall St.
3 months ago
Third Harmonic Bio (NASDAQ:THRD) Is In A Strong Position To Grow Its Business
GlobeNewswire
3 months ago
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
GlobeNewswire
4 months ago
Third Harmonic Bio to Participate in Upcoming Investor Conferences
Compare THRD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THRD Third Harmonic Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.